Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Biotech company Genzyme to pay $22.3 million in Tampa whistle-blower case

TAMPA — A Massachusetts-based biotechnology company has agreed to pay $22.28 million to resolve allegations brought by whistle-blowers in Tampa and Miami that it marketed an inappropriate use for a surgery medication, U.S. government attorneys said.

Genzyme, a corporation known for its research into drugs for rare genetic diseases, is paying the settlement in a lawsuit over Seprafilm, a material it manufactures for use in the operating room.

According to court documents, Genzyme sales representatives encouraged doctors to use the product in a manner not approved by the U.S. Food and Drug Administration, leading to improper claims for reimbursement from hospitals.

"I think these cases are among the most important that our office handles. Health care fraud is a major problem in our country," said A. Lee Bentley III, acting U.S. Attorney for the Middle District of Florida. "These do serve a very important deterrent effect."

The settlement is the result of a civil suit brought under the federal False Claims Act, a 19th-century law that encourages private citizens to expose fraud by government contractors. Whistle-blowers can file suit on behalf of the government and then share in any financial settlement that results.

The Genzyme action was brought by two company sales representatives in 2009.

The amount of the settlement that will be diverted to the whistle-blowers has not yet been determined. One of the private plaintiffs' attorneys, Barry Cohen of Tampa, said they hope to receive between 23 and 24 percent of the settlement, or about $5.2 million.

"They were pharmaceutical salesmen, and they recognized that this was a potential danger," Cohen said. "They saw other people doing it, and they knew it wasn't right."

Sarah Connors, a spokeswoman for Sanofi, Genzyme's parent company, said that Genzyme cooperated with the government investigation and that the company's sales force no longer markets Seprafilm for the unorthodox procedure that spawned the lawsuit.

"Genzyme did take proactive action to address and prohibit this conduct," she said.

According to court documents, Seprafilm is intended to be applied during open surgery to prevent organs and muscle tissue from sticking together. However, the whistle-blowers and lawyers for the federal government alleged that Genzyme sales representatives taught doctors to use it in less invasive procedures — such as laparoscopic or "keyhole" surgeries — by mixing it into a liquidlike "slurry" that could be injected into the body.

Cohen and Bentley said they were not required to prove in the lawsuit that patients had been harmed, only that this use of the drug was not approved by federal regulators and hence not subject to reimbursement by Medicare and Medicaid.

The hefty Genzyme settlement follows two other large payouts secured in recent years by the U.S. Attorney's Office and the Cohen Law Group, including a $217.5 million settlement from WellCare Health Plans and a $10.17 million settlement from Morton Plant Mease Health Care.

Peter Jamison can be reached at or (813) 226-3337. Follow him on Twitter @petejamison.

Biotech company Genzyme to pay $22.3 million in Tampa whistle-blower case 12/23/13 [Last modified: Monday, December 23, 2013 11:27pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times


Join the discussion: Click to view comments, add yours

  1. In advertising, marketing diversity needs a boost in Tampa Bay, nationally


    TAMPA — Trimeka Benjamin was focused on a career in broadcast journalism when she entered Bethune-Cookman University.

    From left, Swim Digital marketing owner Trimeka Benjamin discusses the broad lack of diversity in advertising and marketing with 22 Squared copywriter Luke Sokolewicz, University of Tampa advertising/PR professor Jennifer Whelihan, Rumbo creative director George Zwierko and Nancy Vaughn of the White Book Agency. The group recently met at The Bunker in Ybor City.
  2. Kushner to testify before two intelligence committees


    WASHINGTON— President Donald Trump's senior adviser and son-in-law Jared Kushner is set to make a second appearance on Capitol Hill — he will speak with the House Intelligence Committee on Tuesday, one day after he is scheduled to speak with Senate Intelligence Committee investigators behind closed doors.

    White House senior adviser Jared Kushner is scheduled to testify before the Senate Intelligence Committee and the House Intelligence Committee. [Associated Press]
  3. Rays blow lead in ninth, lose in 10 to Rangers (w/video)

    The Heater

    ST. PETERSBURG — Rays manager Kevin Cash liked the way Alex Cobb was competing Friday night. He liked the way the hard contact made by the Rangers batters went away after the second or third inning. So as the game headed toward the ninth, there was no doubt in Cash's mind that sending Cobb back to the mound was …

    Rays starter Alex Cobb can hardly believe what just happened as he leaves the game in the ninth after allowing a leadoff double then a tying two-run homer to the Rangers’ Shin-Soo Choo.
  4. Exhumation of Dalí's remains finds his mustache still intact


    FIGUERES, Spain — Forensic experts in Spain have removed hair, nails and two long bones from Salvador Dalí's embalmed remains to aid a court-ordered paternity test that may enable a woman who says she is the surrealist artist's daughter to claim part of Dalí's vast estate.

    Salvador Dal? died in 1989 leaving vast estate.
  5. Sessions discussed Trump campaign-related matters with Russian ambassador, U.S. intelligence intercepts show


    WASHINGTON — Russia's ambassador to Washington told his superiors in Moscow that he discussed campaign-related matters, including policy issues important to Moscow, with Jeff Sessions during the 2016 presidential race, contrary to public assertions by the embattled attorney general, current and former U.S. …

    Attorney General Jeff Sessions recused himself from the Russia investigation after meetings with an ambassador were revealed.